Esketamine for Treatment|Resistant Depression

Esketamine for Treatment-Resistant Depression

Esketamine for Treatment-Resistant Depression ... There's good news for people with severe treatment-resistant depression: Esketamine is a groundbreaking therapy ...

Esketamine for treatment‑resistant depression: A review of clinical ...

A total of 14 papers were reviewed, and their results support the recommendation of esketamine for treatment of TRD as an add-on to antidepressants.

SPRAVATO® (esketamine): A Prescription Nasal Spray | SPRAVATO®

If you have treatment-resistant depression (TRD), you may benefit from adding SPRAVATO® to your current oral antidepressant. Click arrow icon. Cost support icon ...

What is esketamine, and is it effective in treating depression?

Similarly, esketamine increases glutamate, the most abundant chemical messenger in the brain, which is thought to treat depression in a way that ...

Esketamine Nasal Spray versus Quetiapine for Treatment-Resistant ...

Esketamine nasal spray, administered in combination with either a selective serotonin reuptake inhibitor (SSRI) or a serotonin–norepinephrine ...

Esketamine for treatment resistant depression: a trick of smoke and ...

Esketamine is the S-enantiomer of ketamine, an FDA-approved anaesthetic, known to cause dissociation and, occasionally, hallucinations. While ...

FDA approves new nasal spray medication for treatment-resistant ...

The US Food and Drug Administration today approved Spravato (esketamine) nasal spray, in conjunction with an oral antidepressant, for the treatment of ...

Nasal esketamine works better than alternative for treatment ...

A nasal spray version of esketamine was more effective for depression that is resistant to treatment than a more commonly used drug.

Benefits and risks of esketamine nasal spray continuation in ...

Intranasal esketamine is the first medication approved by regulatory authorities for difficult to treat depressive episodes that builds directly on the ...

Esketamine (nasal route) - Mayo Clinic

Esketamine nasal spray is used together with an antidepressant taken by mouth, to treat patients with depression who have previously received at least 2 ...

Facts and myths about use of esketamine for treatment-resistant ...

Both FDA (24) and EMA (23) approved esketamine treatment for patients with depression who had tried at least two different antidepressants without gaining ...

Intranasal esketamine treatment using Spravato® for treating severe ...

Intranasal esketamine treatment using Spravato® treats depression by being inhaled through the nose. It targets specific receptors in the ...

Escaping Treatment-Resistant Depression with Esketamine

Esketamine was associated with more adverse effects than quetiapine (92% vs. 78%), mostly dizziness, nausea, and dissociation.

Synthesizing the Evidence for Ketamine and Esketamine in ...

Ketamine and esketamine represent pharmacologically novel treatment avenues for adults with treatment-resistant depression. In addition to ...

How Ketamine Drug Helps with Depression > News > Yale Medicine

The drug is a nasal spray called esketamine, derived from ketamine—an anesthetic that has made waves for its surprising antidepressant effect. Because treatment ...

What Is the Deal With Esketamine? - Psychiatric Times

Esketamine offers a novel treatment approach that can lead to rapid improvement in patients with depression. However, significant logistical ...

A real-world study examining the impact of esketamine nasal spray ...

Esketamine is a novel treatment for people with treatment resistant depression. · There is a need to understand the real-world impact of this treatment.

Esketamine (Spravato) for Treatment-Resistant Depression - AAFP

It is labeled as adjunctive therapy for adults with treatment-resistant depression who are already taking an oral antidepressant.

Esketamine Receives Breakthrough Therapy Designation from U.S. ...

... treatment-resistant depression. ... Esketamine was first granted this designation for treatment-resistant depression in November 2013.

Approval of esketamine for treatment-resistant depression

Esketamine nasal spray plus oral antidepressant in patients with treatment-resistant depression: assessment of long-term safety in a phase 3, open-label study.